Progesterone receptor expression is selectively reduced in adenomyosis among endometriosis-associated lesions: a cross-sectional immunohistochemical study of 118 specimens from 100 women
This cross-sectional study of 118 specimens from 100 women reveals that reduced progesterone receptor expression is a specific characteristic of adenomyosis rather than a generalized feature of all endometriosis-associated lesions, suggesting that lesion type should be considered when selecting progestin therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of women, two painful conditions share a common biological thread: they both rely on the hormone estrogen to grow, and doctors often try to stop them using a different hormone, progesterone. This second hormone usually acts as a brake, telling tissues to calm down or stop growing. In many cases, this treatment works well. However, for a significant number of patients, the medicine fails to relieve their pain or shrink the abnormal tissue. Scientists have long suspected that the reason for this failure is "progesterone resistance," a state where the body's tissues simply stop listening to the hormone's signal. For years, the medical community has treated this resistance as a blanket characteristic of the entire disease, assuming that if a woman has one type of lesion, she likely has the same resistance in all of them. This assumption has guided how doctors choose treatments, often applying the same hormonal strategy to every patient regardless of where the disease is located in their body.
A new study from Tokyo Women's Medical University challenges this broad view by looking closely at the specific locations where these diseases appear. The researchers examined tissue samples from 100 women who had undergone surgery for endometriosis-related conditions. They focused on two distinct types of lesions: adenomyosis, where the tissue grows inside the muscular wall of the uterus, and endometriosis, where similar tissue grows on the ovaries or deep within the pelvis. Using a standard laboratory technique to count the number of progesterone receptors—the molecular "ears" that allow cells to hear the hormone's signal—the team compared the levels found in the uterine muscle against those found in the ovaries and other pelvic sites. They also checked for estrogen receptors to see if the difference was specific to progesterone or a general loss of all hormone sensitivity.
The investigation revealed a clear and surprising distinction. The researchers found that the progesterone receptors were significantly reduced in the adenomyosis lesions inside the uterine wall. In contrast, the lesions found on the ovaries and in the deep pelvis showed normal, healthy levels of these receptors. This difference was not a fluke of the data; it held true even when the researchers accounted for the age of the patients, whether they had gone through menopause, or if they had scar tissue from previous surgeries. The study included 118 tissue samples, and in nine women who happened to have both types of lesions removed during the same operation, the uterine tissue consistently showed lower receptor levels than the tissue taken from their ovaries or pelvis. The pattern was so consistent that the researchers could say with high confidence that the lack of progesterone sensitivity is a specific feature of the adenomyosis lesion, not a general rule for all endometriosis-related disease.
This finding helps explain why some women do not respond to progesterone-based treatments. If a patient has both types of lesions, the medication might successfully calm the ovarian or pelvic growths while failing to affect the uterine growth, leaving the patient with lingering pain. The study also clarified that this issue is specific to progesterone. The levels of estrogen receptors, which are the targets for a different set of hormones, did not show this same drop in the uterine tissue. Instead, the amount of estrogen receptors seemed to be linked to the patient's age, rising slightly as women got older, regardless of where the tissue was located. This separation suggests that the two hormonal pathways operate independently in these diseases.
The implications of this work are practical. It suggests that doctors should not assume all endometriosis-associated lesions are biologically identical. The uterine lesion appears to be a distinct entity with its own unique resistance to progesterone, while the ovarian and pelvic lesions remain sensitive to it. This distinction does not mean that progesterone therapy is useless for everyone, but it does indicate that the choice of treatment might need to be tailored to the specific location of the disease. By recognizing that the uterine tissue is fundamentally different in how it receives hormonal signals, medical professionals can better understand why some treatments work for some parts of the body but not others, paving the way for more precise and effective care in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.